注射用胸腺五肽联合左旋咪唑治疗面部扁平疣临床观察

Clinical observation on treatment of facial verruca plana with thymopetidum for injection combined with levamizole

目的 观察注射用胸腺五肽联合左旋咪唑治疗面部扁平疣的临床效果。方法 将我院皮肤科2010年4月1日~2012年9月25日门诊收治的90例面部扁平疣患者随机分为治疗组和对照组,治疗组使用注射用胸腺五肽联合左旋咪唑治疗,对照组使用胸腺肽肠溶片联合左旋咪唑,疗程均为15~25 d。治疗后,观察比较两组治愈率。结果 治疗组治愈率为75.6%,显著高于对照组的13.3%（P〈0.01）。结论 注射用胸腺五肽联合左旋咪唑治疗扁平疣效果好,治愈率高于胸腺肽肠溶片联合左旋咪唑的给药方案,且不良反应少,安全性高,具有较高的临床应用价值。

Objective To observe the clinical curative effects of thymopetidum for injection combined with levamizole on facial verruca plana. Methods 90 outpatients with facial verruca plana who were treated in the Department of Dermatology between April 1, 2010 and September 25, 2012 were randomly divided into the treatment group and the control group. The treatment group was treated with thymopetidum for injection combined with levamizole, while the control group was treated with thymopeptides enteric- coated tablets combined with levamisole. The course of treatment was 15-25 days. After the treatment, the cure rates of the two groups were observed and compared. Results The cure rate of the treatment group was 75.6% which was significantly higher than that of the control group （13.3%）（P 〈 0.01）. Conclusion Thymopetidum for injection combined with levamizole has good cure effect on facial verruca plana, and its cure rate is better than that of thymopeptides enteric-coated tablets combined with levamisole. Furthermore, this treatment has less side effects and high safety and thus higher clinical application value.